CN

summon up one 's courage for a task! The pharmaceutical industry is entering a new wave of innovation in the valley

release time:2023-02-03|reading:

  It is difficult for people to make strategic decisions objectively because of the optimism under the upsurge of pharmaceutical innovation and the pessimism in the cold winter. Therefore, it is necessary to look at the current industrial cold winter and the coming new wave of innovation from the industrial, historical and global perspectives, remove the industry fog, insight into the future of the industry, and plan the development path from the end.

  The last wave of innovation excitement inevitably has a false fire

  The last round of biomedical innovation benefited from a large number of scientists returning to China for innovation and entrepreneurship. Since about 2010. under the call of China's development to innovation-driven, under the continuous optimization of the business environment and the changing international situation, more than 1400 Chinese scientists in life sciences have returned to China to start businesses, and biotech enterprises have sprung up. According to BCG, there are about 1600 biotechnology companies in China.

  It is difficult to cover up the relatively weak foundation of being the second tier of global innovation. In 2019. the McKinsey report pointed out that China rose from the third tier to the second tier of global pharmaceutical innovation. McKinsey's definition of the global innovation echelon is mainly determined by the "number of pre-marketing clinical research and development trials" and the "number of new drugs on the market". However, at present, a considerable number of innovative drugs in China belong to the fast-flow me-too drugs. First-in-class drugs (FIC) and best-in-class drugs (BIC) are relatively few, and there are few potential international blockbuster-level new drugs that are expected to rewrite the diagnosis and treatment guidelines. At the same time, most of the innovative pharmaceutical enterprises that contribute to innovative drugs have been established for a relatively short time, and the accumulation of technology, experience and capital is relatively weak, and the support of basic research in life science for pharmaceutical innovation is also relatively weak.

  The industry is in full swing. China's biomedical industry needs a lot of learning and exploration, and many enterprises' core technologies are not perfect. Naturally, a considerable number of products belong to the fast-flow me-too drugs, and FIC and BIC are relatively few. There are few international blockbuster new drugs that are potentially expected to rewrite the diagnosis and treatment guidelines, and a large number of hot and low threshold targets are repeatedly developed, and venture capital scrambles for projects. The secondary market valuation is far higher than that of international TOP20 enterprises, The industry is brewing a lot of false fire in its prosperity.

  The cold winter is a self-repair for the innovation of the pharmaceutical industry

  The normal "new policy of clinical value" triggered the industry to enter a cold winter. The new policy of clinical value in November 2021 is not new strictly. Its source is from the Drug Administration Law, and it is also in line with the requirements of ICH. However, in combination with the Sino-American Century War and other events, the pharmaceutical industry began to turn from midsummer to winter. Many innovative drugs failed to achieve the expected commercialization, the share price of the secondary market plummeted, the investment in the primary market was cautious, and a considerable part of biotech's cash flow was tight, and fell into a difficult situation to sustain.

  The change of seasons is also one of the natural laws of the development of the biomedical industry. Excessive target re-development, unreasonable high expectations and unreasonable overvaluation are difficult to last. Therefore, it is a natural adjustment for the industry to shift from midsummer to late autumn and enter the cold winter. It is also a necessary adjustment to meet the next spring.

  The medical winter has its positive significance. The cold winter is naturally cruel for enterprises with insufficient preparation for winter clothes, but for enterprises with preparation or the ability to rise again, most of them are thinking about the irrationality of the last wave of upsurge, the key success factors of enterprises and products in the context of high-quality development, and the internal skills prepared for the next wave of innovation. At the same time, the survival of the fittest of some enterprises and products in the cold winter will also make the market free up valuable capital space and market space for high-value new drugs. Industrial policies will also tend to support innovative drugs with more significant value. Therefore, the rest of the winter will be the king, and the immortal will be stronger.

  When winter comes, can spring be far behind?

  The next wave of innovation is poised. The wave of pharmaceutical innovation brought by the explosive breakthroughs in genomics and proteomics is still on the way. It is reported that there are more than 20000 known targets for human beings, of which there are only more than 600 targets for clinical or marketing of drugs. The development of targets is still in the primary stage. On the other hand, with the breakthrough of new technologies, innovative technologies such as CAR-T/NK, oncolytic virus, stem cells, nucleic acid drugs are emerging and maturing. More and more gene therapy and cell therapy products have entered clinical development and been approved for marketing. Synthetic biology has also made major breakthroughs. New mechanisms, new targets and new technologies are on the eve of a new round of outbreaks.

  The innovative pharmaceutical enterprises that have experienced the baptism of the cold winter are more stable and heavy. Innovative pharmaceutical enterprises that have survived the spring, summer, autumn and winter cycle have not only been recognized by clinical, capital and society for their clinical and commercial value of product pipelines, but also have more mature technologies. More importantly, most of the senior management teams of innovative pharmaceutical enterprises are more committed to the belief pursuit of significant clinical value of products, pay more attention to technology accumulation and breakthrough, pay more attention to international development, and more fear the risk of innovative drug development.

  China's pharmaceutical innovation environment will become better and better. Today's great changes, which have not happened in a century, are accelerating the evolution. The transformation of the pharmaceutical power from a large pharmaceutical country to a powerful pharmaceutical country is intertwined with the great rejuvenation of the Chinese nation. In the context of the country's expectation of the pharmaceutical industry to become bigger and stronger, the continuous renewal and elimination of the drugs that lack significant clinical value advantages, and the making room for supporting pharmaceutical innovation, and the continuous deepening of other policies to encourage innovation, China's pharmaceutical innovation environment will become better and better, and attract more Chinese scientists to return to China for development.

  Rational understanding of the historical stage of China's pharmaceutical innovation

  China's pharmaceutical industry is still in its infancy. Under the history of hundreds of years, China's indigenous pharmaceutical innovation has only been developed for more than 30 years from its infancy. From the perspective of enterprise precipitation, talent cultivation, technology accumulation, policy environment, basic research, etc., it is still immature compared with the established biomedical powers in Europe and the United States. Compared with Japan, which started earlier, it also has many deficiencies in industrial thickness. From a historical point of view, China's biomedical innovation is still in its infancy.

  Thorns and thorns will not change the bright and bright future. Opportunities and accumulation determine the development prospects of the industry. Although the risks of pharmaceutical innovation are extremely high, some countries in the world are not happy to see China's biomedical industry upgrade and seize their jobs and cakes. Although there are still many deficiencies in the current innovation environment, a new wave of innovation is poised to emerge. China's medicine has accumulated a relatively good foundation for innovation, with the deepening of global changes, The rise of China's biomedical industry has taken shape.

  The era calls for high-quality development of the pharmaceutical industry. In 2017. the 19th National Congress put forward a new expression of high-quality development for the first time, which is not only the call of the country from "becoming rich" to "becoming strong", but also the call of China from a big pharmaceutical country to a powerful pharmaceutical country. The "13th Five-Year Plan" basically ended the extensive development stage of China's pharmaceutical industry, and accelerated its progress towards high-quality development. The overall tone of high-quality development requires that Chinese enterprises can develop blockbuster innovative drugs with significant clinical value and can withstand the test of internationalization, and that China can have a number of pharmaceutical enterprises that rank among the top 30 in the world.

  The pharmaceutical industry is working hard and forging ahead

  A number of innovative drugs that are expected to rewrite the relevant diagnosis and treatment guidelines are being cultivated. From the perspective of pipeline development of enterprises such as Baiji Shenzhou, Hehuang Pharmaceutical, Yasheng Pharmaceutical, Legendary Biology, Cornerstone Pharmaceutical and Rongchang Biology, more and more enterprises take solving the unmet clinical needs and developing new drugs with significant clinical value as the primary direction of product development, explore the optimal molecular structure in their respective fields, explore the optimal positioning and demonstrate the clinical value, and often rewrite the relevant diagnosis and treatment guidelines immediately after the product is launched, Create significant value for clinical and patients.

  The internationalization of Chinese pharmaceutical enterprises is opening up. According to incomplete statistics, in 2022. China's pharmaceutical enterprises reached at least 44 cross-border license-out transactions, of which the highest single transaction amount was nearly 10 billion dollars. Innovative drugs from enterprises such as Baiji Shenzhou, Hengrui, Jiakesi, Kangfang, Yasheng, Junshi and Rongchang are speeding up the layout of overseas clinical trials and exploring the international development model.

  Number of overseas clinical trial projects of Chinese enterprises in the past 10 years

  Source: global drug research and development database of Internet

  A number of pharmaceutical enterprises are expected to gradually rank among the top 30 in the world. As a group of leading pharmaceutical enterprises, such as Hengrui, Kelun, China Bio-pharmaceuticals, Fosun, etc., accelerate the innovation transformation and internationalization, and continue to enrich the product pipeline that is expected to cultivate blockbusters, as a group of innovative pharmaceutical enterprises, such as Baiji Shenzhou, Junshi, Hehuang, and Cornerstone, continue to lay out potential blockbuster new drugs that are expected to rewrite the diagnosis and treatment guidelines, and as a new wave of innovation approaches, In the future, a number of innovative pharmaceutical enterprises from China will gradually rank among the top 30 in the world.

  The basic research system and mechanism of life science have been continuously improved. At the national level, the General Secretary stressed that the majority of scientific and technological workers in China should "face the frontiers of science and technology in the world, the main battlefield of the economy, the major needs of the country, and the life and health of the people." The major national research and development plan comprehensively innovatively implements the mechanism of "listing and commanding", and optimizes the management mechanism of scientific and technological innovation; At the social level, a number of enterprises with a broad vision have initiated and supported basic research programs such as the "New Cornerstone Researcher Program", which is known as the "HHMI Program" in China. It is expected to provide outstanding innovation sources for pharmaceutical innovation at the source by facing the forefront of science and technology and encouraging free exploration.

  The innovation ecosystem continues to be optimized. The tone of high-quality development is promoting the implementation of the directors of various CXO institutions, promoting the synchronous resonance between clinical trial institutions and the industry, promoting more scientific medical supervision, promoting the continuous strengthening of innovation support, promoting the production of a number of major findings in basic research, promoting the "double and one stream" talent training, supporting basic research and industrial research, and forming a strong innovation ecosystem with mutual support with pharmaceutical enterprises. Opportunities and challenges coexist. China's pharmaceutical industry in its adolescence has unlimited potential and broad prospects, and will also experience the experience of rain and wind. With the growth of China's biomedical industry, more significant achievements in the future are worth our expectation!

  

Shandong Zhushi Pharmaceutical Group Co., Ltd., founded in 2003, has more than 5000 registered employees. After years of development, it has developed into a diversified industrial cluster integrating medical devices, polymers, cosmetics, health food, daily necessities and biological reagent production, enterprise management consulting and training, real estate economy, pharmaceutical transportation, pharmaceutical printing, etc.


Adhering to the concept of life, health and happiness, the Group provides you with full chain health services.



Tag: Zhushi Pharmaceutical Group Zhushi Pharmacy



HOT


NEW

Home > NEWS > Industry Information

Scan to learn more

Copyright © 2013-2021 Shandong Zhushi Pharmaceutical Group Co., Ltd Copyright Website Map html   鲁ICP备20021214号-8